Som følge af disse benigne påvirkninger fik flere Fablyn- behandlede end placebo- behandlede patienter foretaget en diagnostisk undersøgelse af uterus under PEARL- studiet (se pkt.
As a consequence of these benign effects, more FABLYN-treated patients had a diagnostic uterine procedure compared to placebo-treated patients in the PEARL trial (see section 5.1).